

Patterns of Care in Medical Oncology: Current Practice Patterns of General Medical Oncologists — Multiple Myeloma Module

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The induction regimen recommended by most of the US-based general oncologists surveyed for an otherwise healthy 60-year-old patient with ISS Stage II, standard-risk multiple myeloma (MM) is _____.
 - RVD (lenalidomide/bortezomib/dexamethasone)
 - RD or Rd (lenalidomide/dexamethasone)
 - CyBorD (cyclophosphamide/bortezomib/dexamethasone)
- The maintenance therapy selected by the majority of the surveyed general oncologists for a 60-year-old patient with Stage II MM and normal cytogenetics/FISH who achieves a complete response after receiving induction therapy followed by an autologous stem cell transplant (ASCT) is _____.
 - Bortezomib
 - Lenalidomide
 - No maintenance therapy
- The agent most frequently used by the surveyed general oncologists to prevent herpes zoster reactivation in patients with MM who receive bortezomib is _____.
 - Famciclovir
 - Valacyclovir
 - Acyclovir
- Maintenance therapy for only 1 year is usually recommended by the majority of the surveyed general oncologists for younger, otherwise healthy patients with standard-risk MM who respond to induction therapy and ASCT.
 - True
 - False
- The majority of the general oncologists surveyed generally administer dexamethasone in combination with bortezomib to most patients with MM who are receiving maintenance therapy.
 - True
 - False
- The faculty and most of the general oncologists surveyed would counsel patients receiving post-transplant lenalidomide maintenance that this therapy incurs no increased risk of second primary cancer.
 - True
 - False
- A majority of the general oncologists surveyed would use the following route and schedule of administration for bortezomib as part of induction therapy:
 - Subcutaneous, twice weekly
 - Subcutaneous, once weekly
 - Intravenous, twice weekly
- The recommendation of both faculty members and a majority of the surveyed general oncologists for the initiation of maintenance therapy for patients with MM who are not eligible for transplant and are receiving lenalidomide- or bortezomib-based therapy is after _____.
 - Four cycles
 - Six cycles
 - The patient achieves a maximal response

POST-TEST

Patterns of Care in Medical Oncology: Current Practice Patterns of General Medical Oncologists — Multiple Myeloma Module

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. For an otherwise healthy 77-year-old patient with MM who responds to front-line therapy but is not eligible for transplant, the preferred starting dose of lenalidomide maintenance therapy is _____.
- a. 10 or 15 mg
 - b. 20 mg
 - c. 25 mg
10. The faculty and most of the general oncologists surveyed would not recommend thromboprophylaxis for patients with MM who are receiving maintenance therapy with lenalidomide.
- a. True
 - b. False